A phase 2 study of fosaprepitant combined with high-dose dexamethasone for Japanese cancer patients receiving highly emetogenic chemotherapy

PURPOSE: Combination therapy of fosaprepitant, dexamethasone (DEX) and a serotonin (5-HT(3)) receptor antagonist is a standard antiemetic prophylaxis for patients receiving highly emetogenic chemotherapy (HEC). However, the appropriate dose of DEX has not been established in Japan. This study determ...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumagai, Hozumi, Kusaba, Hitoshi, Yamanaka, Takeharu, Nio, Kenta, Inadomi, Kyoko, Takayoshi, Kotoe, Ito, Mamoru, Tamura, Shingo, Makiyama, Akitaka, Makiyama, Chinatsu, Hirano, Gen, Shibata, Yoshihiro, Shirakawa, Tsuyoshi, Mitsugi, Kenji, Ariyama, Hiroshi, Esaki, Taito, Akashi, Koichi, Baba, Eishi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023705/
https://www.ncbi.nlm.nih.gov/pubmed/29923992
http://dx.doi.org/10.1097/MD.0000000000011042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023705/
https://www.ncbi.nlm.nih.gov/pubmed/29923992
http://dx.doi.org/10.1097/MD.0000000000011042

Ejemplares similares